Current Approach to Treatment for Central Serous Chorioretinopathy. Review

Central serous chorioretinopathy (CSC) is a disease of complex origin and unknown etiology. Traditionally, two clinical forms of CSC are verified in accordance with the activity and duration of the pathological process: classic acute form and chronic CSC. Nowadays, there is no unified concept accepted for the management of patients with this disease, particular difficulties exist in cases of chronic CSC. This literature review highlights current trends and approaches to the treatment of CSC patients — from focal laser photocoagulation to physical methods oh therapy. The therapeutic approach as a whole depends on the form of the CHS. In most cases of the acute form of CSF, spontaneous regression, spontaneous adhesion of RPE detachment and retinal neuroepithelium are noted within several months from the onset of the disease. Therapy for the chronic form of this disease is still a difficult task and a controversial issue. Direct laser coagulation of the retina at the oozing point is recognized as the most effective method of therapy for acute typical form of CSF. In the chronic form of CSC, photodynamic therapy, transpupillary thermotherapy and subthreshold micropulse laser exposure are used. The goal of drug therapy for CSF is to activate the processes of resorption of serous fluid from the subretinal or subpigmented space, reduce the activity of pathological processes in the choroid, and improve trophism and metabolism. The currently used methods of treating chronic CSH have a number of disadvantages and variable efficacy. The existence of treatment-resistant cases is the subject of further research and clinical research. The development of new physical and physiopharmacological methods of treatment for CSF is perspective.

1. Chhablani J. Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents. Retina. 2015;35(12):2489–2497. DOI: 10.1097/IAE.0000000000000655

2. Maltsev D.S., Fomin A.V., Kulikov A.N., Vasiliev A.S. Evaluation of choriocapillaris with high-speed spectral-domain optical coherence tomography angiography and image averaging. Annals of Ophthalmology = Vestnik oftal’mologii. 2021;137(3):76–84 (In Russ.). DOI: 10.17116/oftalma202113703176

3. Stoiukhina A.S., Budzinskaia M.V., Stoyukhin S.G., Aslamazova A.E. Optical coherence tomography angiography in ophthalmic oncology. Annals of Ophthalmology = Vestnik oftal’mologii. 2019;135(1):104–111 (In Russ.). DOI: 10.17116/oftalma2019135011104

4. Maltsev D.S., Kulikov A.N., Chhablani J., Kutik D.S., Arsenov N.V. Optical coherence tomography in diagnostics and treatment of central serous chorioretinopathy. Annals of Ophthalmology = Vestnik oftal’mologii. 2018;134(6):15–24 (In Russ.). DOI: 10.17116/oftalma201813406115

5. Rijssen T.J. Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019;73:100770. DOI: 10.1016/j.preteyeres.2019.07.003

6. Iacono P., Toto L., Costanzo E., Varano M., Parravano M.C. Pharmacotherapy of Central Serous Chorioretinopathy: A Review of the Current Treatments. Curr Pharm Des. 2018;24(41):4864–4873. DOI: 10.2174/1381612825666190123165914

7. Gülkaş S., Şahin Ö. Current Therapeutic Approaches to Chronic Central Serous Chorioretinopathy. Turk J Ophthalmol. 2019;49(1):30–39. DOI: 10.4274/tjo.galenos.2018.49035

8. Semeraro F., Morescalchi F., Russo A., Gambicorti E., Pilotto A., Parmeggiani F., Bartollino S., Costagliola C. Central Serous Chorioretinopathy: Pathogenesis and Management. Clin Ophthalmol. 2019;13:2341–2352. DOI: 10.2147/OPTH.S220845

9. Daruich A., Matet A., Dirani A., Bousquet E., Zhao M., Farman N., Jaisser F., Behar-Cohen F. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin.Eye Res. 2015;48:82–118. DOI: 10.1016/j.preteyeres.2015.05.003

10. Gemenetzi M., De Salvo G., Lotery A.J. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye. 2010;24(12):1743–1756. DOI: 10.1038/eye.2010.130

11. Chhablani J. Antiangiogenics in choroidal neovascularization associated with laser in central serous chorioretinopathy. Retina. 2016;36(5):901–908. DOI: 10.1097/IAE.0000000000000804

12. Sivaprasad S., Elagouz M., McHugh D., Shona O., Dorin G. Micropulsed diode laser therapy: evolution and clinical applications. Surv Ophthalmol. 2010;55(6):516–530. DOI: 10.1016/j.survophthal.2010.02.005

13. Sramek C., Mackanos M., Spitler R., Leung L.S., Nomoto H., Contag C.H., Palanker D. Non-damaging retinal phototherapy: dynamic range of heat shock protein expression. Investig Ophthalmol Vis Sci. 2011;52(3):1780–1787. DOI: 10.1167/iovs.10-5917

14. Scholz P., Altay L., Fauser S. A review of subthreshold micropulse laser for treatment of macular disorders. Adv. Ther. 2017;34(7):1528–1555. DOI: 10.1007/s12325-017-0559-y

15. Chen S.N., Hwang J.F., Tseng L.F., Lin C.J. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology. 2008;115(12):2229–2234. DOI: 10.1016/j.ophtha.2008.08.026

16. Dijk E.H.C. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the place trial. Ophthalmology. 2018;125(10):1547–1555. DOI: 10.1016/j.ophtha.2018.04.021

17. Ardamakova A.V., Bol’shunov A.V., Ilyina T.S., Fedoruk N.A., Siplivyĭ V.I. Transpupillary laser photocoagulation of ocular fundus: history, the present, and the future. Annals of Ophthalmology = Vestnik oftal’mologii. 2017;133(1):81–87 (In Russ.). DOI: 10.17116/oftalma2017133181-87

18. Desmettre T., Maurage C.A., Mordon S. Heat shock protein hyperexpression on chorioretinal layers after transpupillary thermotherapy. Investig. Ophthalmol. Vis. Sci. 2001;42(12):2976–2980.

19. Hussain N., Khanna R., Hussain A., Das T. Transpupillary thermotherapy for chronic central serous chorioretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2006;244(8):1045–1051. DOI: 10.1007/s00417-005-0175-4

20. Shukla D., Kolluru C., Vignesh T.P., Karthikprakash S., Kim R. Transpupillary thermotherapy for subfoveal leaks in central serous chorioretinopathy. Eye. 2008;22(1):100–106. DOI: 10.1038/sj.eye.6702449

21. Mathur V., Parihar J., Maggon R., Mishra S.K. Role of transpupillary thermotherapy in central serous chorio-retinopathy. Med. J. Armed Forces India. 2009;65(4):323–327. DOI: 10.1016/S0377-1237(09)80092-0

22. Giudice G.L., Belvis V., Tavolato M., Galan A. Large-spot subthreshold transpupillary thermotherapy for chronic serous macular detachment. Clin. Ophthalmol. 2011;5:355–360. DOI: 10.2147/OPTH.S16014

23. Schlotzer-Schrehardt U., Viestenz A., Naumann G.O., Laqua H., Michels S., Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch. Clin. Exp. Ophthalmol. 2002;240(9):748–757. DOI: 10.1007/s00417-002-0517-4

24. Shiode Y., Morizane Y., Kimura S., Hosokawa M., Kawata T., Doi S., Hosogi M., Fujiwara A., Shiraga F. Comparison of halving the irradiation time or the verteporfin dose in photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2015;35(12):2498–2504. DOI: 10.1097/iae.0000000000000621

25. Shin J.Y., Woo S.J., Yu H.G., Park K.H. Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2011;31(1):119–126. DOI: 10.1097/IAE.0b013e3181e378f2

26. Neves F., Costa J., Fonseca S., Silva L., Agrelos L. Half-dose photodynamic therapy for chronic central serous chorioretinopathy: efficacy and safety outcomes in real world. Photodiagn. Photodyn. Ther. 2016;14:173–177. DOI: 10.1016/j.pdpdt.2016.04.012

27. Alkin Z., Perente I., Ozkaya A., Alp D., Agca A., Aygit E.D., Korkmaz S., Yazici A.T., Demirok A. Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Clin. Ophthalmol. 2014;8:685–690. DOI: 10.2147/OPTH.S58617

28. Maruko I., Iida T., Sugano Y., Ojima A., Ogasawara M., Spaide R.F. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology. 2010;117(9):1792–1799. DOI: 10.1016/j.ophtha.2010.01.023

29. Dijk E.H.C., Dijkman G., Theelen T., Hoyng C.B., Boon C.J.F. Short-term findings on optical coherence tomography and microperimetry in chronic central serous chorioretinopathy patients treated with half-dose photodynamic therapy. Retin. Cases Brief Rep. 2018;12(4):266–271. DOI: 10.1097/ICB.0000000000000498

30. Nicolo M., Eandi C.M., Alovisi C., Grignolo F.M., Traverso C.E., Musetti D., Cardillo Piccolino F. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am. J. Ophthalmol. 2014;157(5):1033–1037. DOI: 10.1016/j.ajo.2014.01.022

31. Liu C.F., Chen L.J., Tsai S.H., Lai C.C., Chan W.C., Wu W.C., Wang N.K., Chen K.J., Hwang Y.S., Chen Y.P., Yeung L. Half-dose verteporfin combined with half-fluence photodynamic therapy for chronic central serous chorioretinopathy. J. Ocul. Pharmacol. Ther. 2014;30(5):400–405. DOI: 10.1089/jop.2013.0169

32. Zhao M. A 50 % vs 30 % dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. JAMA Ophthalmol. 2015;133(3):333–340. DOI: 10.1001/jamaophthalmol.2014.5312

33. Uetani R., Ito Y., Oiwa K., Ishikawa K., Terasaki H. Half-dose vs one-thirddose photodynamic therapy for chronic central serous chorioretinopathy. Eye. 2012;26(5):640–649. DOI: 10.1038/eye.2012.66

34. Kim K.S., Lee W.K., Lee S.B. Half-dose photodynamic therapy targeting the leakage point on the fluorescein angiography in acute central serous chorioretinopathy: a pilot study. Am. J. Ophthalmol. 2014;157(2):366–373. DOI: 10.1016/j.ajo.2013.10.013

35. Yannuzzi L.A., Slakter J.S., Gross N.E., Spaide R.F., Costa D., Huang S.J., Klancnik J,M. Jr, Aizman A. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003;23(3):288–298. DOI: 10.1097/00006982-200306000-00002

36. Pikkel J., Beiran I., Ophir A., Miller B. Acetazolamide for central serous retinopathy. Ophthalmology. 2002;109(9):1723–1725. DOI: 10.1016/s0161-6420(02)01157-0

37. Astakhov Yu.S., Butin E.V., Morozova N.V., Sokolov V.O., Rakitskiy A.V., Florentseva S.S. The local carbonic anhydrase inhibitor Trusopt treatment of central serous chorioretinopathy. Ophthalmology journal = Oftal’mologicheskie vedomosti. 2010;3(1):63–66 (In Russ.).

38. Bousquet E., Beydoun T., Zhao M., Hassan L., Offret O., Behar-Cohen F. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2013;33(10):2096–2102. DOI: 10.1097/IAE.0b013e318297a07a

39. Bousquet E. Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina. 2015;35(12):2505–2515. DOI: 10.1097/IAE.0000000000000614

40. Pichi F., Carrai P., Ciardella A., Behar-Cohen F., Nucci P., Central Serous Chorioretinopathy Study Group. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol. 2017;37(5):1115–1125. DOI: 10.1007/s10792-016-0377-2

41. Artunay O., Yuzbasioglu E., Rasier R., Sengul A., Bahcecioglu H. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr. Eye Res. 2010;35(2):91–98. DOI: 10.3109/02713680903428306

42. Kim M., Lee S.C., Lee S.J. Intravitreal ranibizumab for acute central serous chorioretinopathy. Ophthalmologica. 2013;229(3):152–157. DOI: 10.1159/000345495

43. Arslan U., Özmert E. Treatment of resistant chronic central serous chorioretinopathy via platelet-rich plasma with electromagnetic stimulation. Regenerative medicine. 2020;15(8):2001-2014. DOI: 10.2217/rme-2020-0056

44. Shchuko A.A., Iur’eva T.N., Zlobina A.N. Features of psycho-emotional state of patients with central serous chorioretinopathy. Annals of Ophthalmology = Vestnik oftal’mologii. 2017;133(2):70–74 (In Russ.). DOI: 10.17116/oftalma2017133270-74